Development of breast cancer on the basis of new data from the Czech National oncologic registry and data of other sources

Česká verzia

Authors: Ladislav Dušek ¹; Ondřej Májek ¹; Jan Mužík ¹; Tomáš Pavlík ¹; Jakub Gregor ¹; Miroslava Skovajsová ²; Jan Daneš ³
Authors place of work: Institut biostatistiky a analýz, Masarykova univerzita, Brno, ředitel doc. RNDr. Ladislav Dušek, Ph. D. ¹; Breast Unit Prague, Praha, primářka MUDr. Miroslava Skovajsová, Ph. D. ²; Radiodiagnostická klinika 1. LF UK a Všeobecná fakultní nemocnice, Praha, přednosta prof. MUDr. Jan Daneš, CSc. ³
Published in the journal: Prakt Gyn 2013; 17(1): 31-39
Category: Oncogynecology: Original Article

Summary

The work summarizes the analyses of the new available data from the Czech National Cancer Registry (NOR) with a focus on breast cancer (C50 and D05) which in the general NOR data for the year 2010 represented 8.4 % of all reported malignant tumours. Based on these analyses, demographic data and the Czech Republic Register of Death Records, the study describes and predicts the development of incidence and prevalence of patients with breast cancer for the year 2013.

Key words:
Czech National Cancer Registry – breast carcinoma/cancer – epidemiolgy – mammographic screening

Zdroje

1. Dušek L, Mužík J, Kubásek M et al. Epidemiologie zhoubných nádorů v České republice [online]. Masarykova univerzita 2007. Dostupný z WWW: <http://www.svod.cz>.

2. Giordano L, Karsa LV, Tomatis M et al. Mammographic screening programmes in Europe: organization, coverage and participation. J Med Screen 2012; 19(Suppl 1): 72–82.

3. Hakama M, Coleman MP, Alexe DM et al. Cancer screening: evidence and practice in Europe 2008. Eur J Cancer 2008; 44(10): 1404–1413.

4. Karsa L, Anttila A, Ronco G. et al. Cancer Screening in the European Union: Report on the implementation of the Council Recommendation on cancer screening. European Communities: Luxembourg 2008. ISBN 978–92–79–08934–3.

5. Majek O, Danes J, Skovajsova M et al. Breast cancer screening in the Czech Republic: time trends in performance indicators during the first seven years of the organised programme. BMC Public Health 2011; 11: 288. Dostupný z doi: 10.1186/1471–2458–11–288.

6. Majek O, Danes J, Zavoral M et al. Czech National Cancer Screening Programmes in 2010. Klin Onkol 2010; 23(5): 343–353.

7. Nystrom L, Rutqvist L, Wall S et al. Breast cancer screening with mammography: overview of Swedish randomised trials. Lancet 1993; 341(8851): 973–978.

8. Pavlik T, Majek O, Muzik J et al. Estimating the number of colorectal cancer patients treated with anti-tumour therapy in 2015: the analysis of the Czech National Cancer Registry. BMC Public Health 2012; 12(1): 117. Dostupný z doi: 10.1186/1471–2458–12–117.

9. Pavlík T, Dušek L, Májek O et al. Five-Year Survival Rates of Cancer Patients in the Czech Republic. In: Dušek L (ed). Czech Cancer Care in Numbers 2008–2009. Praha: Grada Publishing 2009. ISBN 978–80–47–3244–2.

10. Perry N, Broeders M, De Wolf C. et al. European guidelines for quality assurance in breast cancer screening and diagnosis, 4th ed. Office for Official Publications of the EC: Luxembourg 2006. ISBN 92–79–01258–4.

11. Tabar L, Fagerberg G, Duffy S. et al. The Swedish two county trial of mammographic screening for breast cancer: recent results and calculation of benefit. J Epidemiold Community Health 1989; 43(2): 107–114.

12. Vainio H, Bianchini F (eds). Breast cancer screening – IARC handbooks of cancer prevention volume 7. IARCPress: Lyon 2002: 1–23.